-
- Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO
- Novotech, the Asia-Pacific CRO, has again won the prestigious Asia-Pacific CRO of the year awarded by leading analyst firm Frost & Sullivan. This is the fifth year Novotech has been awarded the top CRO for the region which focusses on best practices in clinical research...
- 2019-05-31
-
- Seodong Medical Launches Globally Recognized Innovative Device for Treating Dry Eye Syndrome
- Innovative products of Seodong Medical Co., a leading dry eye syndrome treatment devices developer, are gaining significant popularity in Korea and other countries as they enhance health of eyeballs. Seodong Medical’s NURIEYE-5800, a medical vibrator, is an innovative...
- 2019-03-22
-
- Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
- Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the tr...
- 2019-03-19
-
- Solasia Files New Medical Device Application for episil® in South Korea
- Solasia Pharma K.K. (TOKYO:4597, Headquarters:Tokyo, Japan, President & CEO:Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially announced that the Company has filed a New Medical Device Application for episil® ...
- 2019-03-19
-
- Octapharma Group Reports Strong Results for 2018
- Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am particularly pleased with the important regulatory approvals for our new fibrinogen concentrate, fibryga®, w...
- 2019-03-15
-
- Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Ozanimod is an oral...
- 2019-03-12
-
- Masimo Announces CE Marking of Pediatric Indication for Next Generation SedLine® Brain Function Monitoring
- Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine® brain function monitoring for pediatric patients (1-18 years of age). With this clearance, the benefits of Next Generation SedLine are available for all patients one year old and above in ...
- 2019-03-06
-
- Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development
- Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test. The test would be used in combination with GNA's portable molecular diagnostic platfo...
- 2019-02-28
-
- LMD’s Smartphone-Integrated e-Checkup™ System Makes Medically-Accurate Personal Health Monitoring a Reality
- Leman Micro Devices (LMD), the developer of regulated consumer healthcare products that is backed by major players within the mobile device industry, has announced that e-Checkup™ is now poised to be integrated into the new generation of smartphones. Medically-accurat...
- 2019-02-27
-
- Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer
- Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for...
- 2019-02-25
-
- ResMed and Fisher & Paykel Healthcare Announce Settlement of Global Patent Infringement Litigation
- ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. The settlement involves no payment or admission of...
- 2019-02-22
-
- Boehringer Ingelheim and Lilly’s CAROLINA® cardiovascular outcome trial for Trajenta® meets primary endpoint of non-inferiority compared to glimepiride
- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority of Trajenta® (linagliptin) vs glimepir...
- 2019-02-20
-
- Saudi Arabia Ministry of Health and Masimo Announce Automation of National Neonatal CCHD Screening Process Using Masimo Technology
- Recently at Arab Health 2019, the Saudi Arabia Ministry of Health (MOH) and Masimo (NASDAQ: MASI) jointly announced the implementation of an automation solution designed to streamline the process of critical congenital heart disease (CCHD) screening of newborns using Ma...
- 2019-02-19
-
- SpeeDx Develops Multiplex Test for Respiratory Viruses
- SpeeDx Pty. Ltd. today announced submission of their PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA). The company anticipates clearance in time for the Australian 2019 flu season. The test utilises SpeeDx market-leading PlexPCR® multiplex techno...
- 2019-02-14
-
- European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment of adult patients with previously untreated CD30+ Stage IV Hod...
- 2019-02-13
-
- Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL - a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A- at EAHAD 2019
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, has today announced results from its phase IIIb/IV clinical trial for ADYNOVATE at the 12th Annual Congress of the European Association of Haemoph...
- 2019-02-08
-
- Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
- Takeda Pharmaceutical Company Limited [TSE:4502 / NYSE:TAK] (“Takeda”) today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study...
- 2019-01-30
-
- Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments
- Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together speciali...
- 2019-01-23
-
- Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical Officer
- Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, announced today the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk ...
- 2019-01-18
-
- Mobi Is Here: ResMed’s First Portable Oxygen Device Now Widely Available in the U.S.
- ResMed (NYSE: RMD, ASX: RMD), a leader in respiratory care medical devices and out-of-hospital care software, today announced that its premier portable oxygen concentrator, Mobi, is now widely available in the United States. Mobi offers an optimal balance of oxygen deli...
- 2019-01-10
- 기획특집 2 - 미세먼지더보기
-
-
- 호산구 수치 높을수록, COPD 환자 생존률 올라간다
- 만성폐쇄성폐질환(COPD) 환자의 생존률이 혈액 호산구 수치가 높을수록 올라간다는 연구결과가 나왔다. 강원대병원 환경보건센터(김우진 센터장)는 분진지역 COPD 코호트 연구팀(홍윤기 호흡기내과 교수팀)이 전국 단위의 COPD 코호트 (KOLD cohort)와 공동으로 COPD 환자들의 혈액, 흉부 CT, 생존률을 분석한 결과,...
-
- 식약처, 자외선차단제 등 27개 제품 미세먼지 차단 효과 없다
- 식품의약품안전처(처장 류영진)는 인터넷쇼핑몰 등에서 유통되는 화장품 중 미세먼지 차단 세정에 효과가 있다고 광고 판매하는 자외선차단제, 보습제, 세정제 등 53개 제품을 조사한 결과, 27개 제품이 미세먼지 차단 세정 효과가 없는 것으로 밝혀졌다고 13일 발표했다.이번 점검은 미세먼지로부터 피부를 ...
-
- 미세먼지 대처요령, 마스크 착용 + 수분섭취 + 외출 후 손씻기 구강 코 세척
- 미세먼지가 기승을 부리는 계절이 돌아오면서 미세먼지에 대한 바람직한 대처 방법에 대한 관심이 고조되고 있다.우선 가급적 호흡기 질환을 가지고 있거나 노약자, 면역 저하자의 경우에는 미세먼지 농도가 높을 때에는 외출을 피하고 꼭 외출해야 할 때에는 마스크를 착용하는 게 좋다. 마스크 중에서도...
-
도로포장 신기술로 미세먼지 잡는다
-
미세먼지 영향, 알레르기 비염 환자도 급증했다
